Clinical Trials Logo

Clinical Trial Summary

The purpose of this randomized study is to determine the safety and efficacy of GPX-001 a.k.a REQORSA ( a TUSC2, tumor suppressor gene, encapsulated by non-viral lipid nanoparticles) in combination with pembrolizumab in patients with previously treated NSCLC. The study will be conducted in 2 phases, a Dose Escalation Phase (Phase 1) and an Expansion Phase (Phase 2). In Phase 1, patients will be enrolled in sequential cohorts treated with successively higher doses of GXP-001 in combination with pembrolizumab. In Phase 2, patients will be randomized to receive GXP-001 with pembrolizumab or docetaxel +/- ramucirumab (active comparator).


Clinical Trial Description

ONC-004 is a multi-center, open-label 2-arm study of GPX-001 in combination with pembrolizumab versus docetaxel +/- ramucirumab (active comparator) in previously treated NSCLC with any PD-L1 TPS and NOT considered refractory to pembrolizumab, as defined by having achieved at least a 3-month clinical benefit to previous pembrolizumab-containing treatment. The total duration of study for each patient will be dependent upon the safety, tolerability, and efficacy of the combination regimen of GPX-001 and pembrolizumab. The Phase 1 portion of the study will involve a 3+3 dose escalation schema of GPX-001 up to 0.12 mg/kg in combination with a fixed dose of pembrolizumab (200 mg) administered once via intravenous (IV) infusion during each 21-day treatment cycle. Three GPX-001 doses will be tested (0.06, 0.09 and 0.12 mg/kg administered on Day 1 of a 21-day treatment cycle). The Phase 2 portion of the study is a randomized, open-label 2-arm study of GPX-001 in combination with pembrolizumab versus docetaxel ± ramucirumab. In Phase 2, 126 patients will be randomized 2:1 to the combination versus active comparator treatment arms, respectively. The 84 patients randomized to the combination arm will receive GPX-001, at the RP2D identified in Phase 1, in combination with 200 mg pembrolizumab either during each 21-day cycle until disease progression or unacceptable toxicity as determined by the investigator. The 42 patients randomized to the active comparator arm will receive docetaxel at the FDA-approved dose of 75 mg/m2 every 21 days until disease progression or unacceptable toxicity as determined by the investigator. Investigators are permitted to administer docetaxel in combination with ramucirumab at their discretion. All patients will be assessed radiologically for tumor response until disease progression according to RECIST 1.1 criteria approximately every 6-8 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05062980
Study type Interventional
Source Genprex, Inc.
Contact Shannon Inman
Phone 1-877-774-GNPX
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date December 2021
Completion date December 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Recruiting NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Recruiting NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab +Dendritic Cells in NSCLC Phase 2
Recruiting NCT04875585 - Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC Phase 2
Not yet recruiting NCT05013099 - Study of 89Zr-Df-crefmirlimab PET/CT in Subjects With Advanced or Metastatic Malignancies Phase 2
Not yet recruiting NCT05014035 - Feasibility of a Hybrid Delivery of Home-based Cluster Set Resistance Training in Lung Cancer N/A
Not yet recruiting NCT05014815 - Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer Phase 2
Not yet recruiting NCT04629300 - Supportive Care Mobile Application for Patients With NSCLC N/A
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Completed NCT03780010 - Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC Phase 1
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Active, not recruiting NCT02136355 - A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer Phase 2